Data as of Nov 26
| 0.00 / 0.00%|
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Its most advance product candidate, is the subject of SEAMLESS, a phase 3 trail being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia in the elderly, and other studies for myelodysplastic syndromes, chronic lymphocytic leukemia and solid tumors, including breast, lung, ovarian and pancreatic cancer and in particular those carrying BRCA mutations. The company's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Cyclacel Pharmaceuticals was founded by Ronald J. Berenson, David P. Lane and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
|Spiro Rombotis||President, Chief Executive Officer & Director|
|Paul McBarron||COO, CFO, Secretary, Director & Executive VP|
|David Glover||Chief Scientist|
|Susan Davis||Director-Business Development|
|Bill Harris||Corporate Controller|